Long-Term Prognosis of Patients with Obscure Gastrointestinal Bleeding: A Retrospective Cohort Study

Digestion ◽  
2019 ◽  
Vol 100 (1) ◽  
pp. 37-44
Author(s):  
Makoto Arai ◽  
Tomoaki Matsumura ◽  
Yuki Ohta ◽  
Soichiro Kiyono ◽  
Masahiro Hayashi ◽  
...  
Keyword(s):  
Cohort Study ◽  
Gastrointestinal Bleeding ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Obscure Gastrointestinal Bleeding ◽  
Long Term Prognosis

scholarly journals Impact of Antiviral Treatment on Long-Term Prognosis in Non-Immunocompromised Patients With CMV Reactivation

2021 ◽  
Author(s):  
Ga Eun Park ◽  
Hyun Kyun Ki ◽  
Jae-Hoon Ko
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Antiviral Treatment ◽  
Treated Group ◽  
Immunocompromised Patients ◽  
Ganciclovir Treatment ◽  
Long Term Prognosis ◽  
Cmv Reactivation

Abstract Background. Reactivation of human cytomegalovirus (CMV) occurs in non-immunocompromised patients with or without specific organ involvement, but it is still unknown whether it has a clinical implication on long-term prognosis or not.Methods. A retrospective cohort study evaluating non-immunocompromised adult patients with CMV reactivation was conducted during the period between January 2010 and February 2018. Patients were divided into ganciclovir-treated and non-treated groups. Patients who died within 30 days from CMV reactivation were excluded as they died from complex causes of conditions. Survivors were followed for 30-months to evaluate long-term prognosis.Results. A total of 136 patients with CMV reactivation was included, consisting of 66 ganciclovir-treated (48.5%) and 70 non-treated (51.5%) patients. Overall, patients were old-aged (median 70 years old) and most were treated with pneumonia of any cause (91.2%). More patients in ganciclovir-treated group were treated at intensive care unit (43.9% vs 24.3%, respectively) and had higher viral load over 5,000 copies/ml (48.5% vs 22.9%) than non-treated group (all P < 0.05). Primary and secondary endpoints including 30-months survival (28.0 vs 38.9%, respectively) and 12-months survival (40.3% vs 49.2%) were not statistically different between the ganciclovir-treated and non-treated groups. In the multivariate analyses, ganciclovir treatment was not associated with 30-months survival (HR 1.307 95% CI 0.759-2.251) and 12-months survival (HR 1.533 95% CI 0.895-2.624).Conclusion. In a retrospective cohort study evaluating non-immunocompromised patients with CMV reactivation, ganciclovir treatment was not associated with long-term prognosis. Antiviral treatment in this condition would not be necessary unless organ involvement is suspected.

scholarly journals Impact of antiviral treatment on long-term prognosis in non-immunocompromised patients with CMV reactivation

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Ga Eun Park ◽  
Hyun Kyun Ki ◽  
Jae-Hoon Ko
Keyword(s):  
Cohort Study ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Antiviral Treatment ◽  
Treated Group ◽  
Immunocompromised Patients ◽  
Ganciclovir Treatment ◽  
Long Term Prognosis ◽  
Cmv Reactivation

Abstract Background Reactivation of human cytomegalovirus (CMV) occurs in non-immunocompromised patients with or without specific organ involvement, but it is still unknown whether it has a clinical implication on long-term prognosis or not. Methods A retrospective cohort study evaluating non-immunocompromised adult patients with CMV reactivation was conducted during the period between January 2010 and February 2018. Patients were divided into ganciclovir-treated and non-treated groups. Patients who died within 30 days from CMV reactivation were excluded as they died from complex causes of conditions. Survivors were followed for 30-months to evaluate long-term prognosis. Results A total of 136 patients with CMV reactivation was included, consisting of 66 ganciclovir-treated (48.5%) and 70 non-treated (51.5%) patients. Overall, patients were old-aged (median 70 years old) and most were treated with pneumonia of any cause (91.2%). More patients in ganciclovir-treated group were treated at intensive care unit (43.9% vs 24.3%, respectively) and had higher viral load over 5000 copies/ml (48.5% vs 22.9%) than non-treated group (all P < 0.05). Primary and secondary endpoints including 30-months survival (28.0 vs 38.9%, respectively) and 12-months survival (40.3% vs 49.2%) were not statistically different between the ganciclovir-treated and non-treated groups. In the multivariate analyses, ganciclovir treatment was not associated with 30-months survival (HR 1.307, 95% CI 0.759–2.251) and 12-months survival (HR 1.533, 95% CI 0.895–2.624). Conclusion In a retrospective cohort study evaluating non-immunocompromised patients with CMV reactivation, ganciclovir treatment was not associated with long-term prognosis. Antiviral treatment in this condition would not be necessary unless organ involvement is suspected.

Sign in / Sign up

Export Citation Format

Share Document